Literature DB >> 6669635

Zopiclone: sleep and performance studies in healthy man.

A N Nicholson, B M Stone.   

Abstract

Effects of 2.5, 5.0, 7.5, and 10.0 mg zopiclone on sleep and on performance the next day were studied in 6 healthy adult males aged between 21 and 33 years. The experiment was double-blind and placebo controlled. 5.0 and 10.0 mg zopiclone decreased the amount of awake activity and drowsy (stage 1) sleep over the first 6 h of sleep, but this effect was only present for the whole sleep period with the 10.0-mg dose. The duration and percentage of stage 3 sleep were increased with 7.5 mg. The 7.5- and 10.0-mg doses increased the combined duration of stages 2, 3, and 4 sleep over the first 6 h and over the whole night. The first period of rapid eye movement sleep was delayed with 7.5 mg, and with 10.0 mg the time spent in rapid eye movement sleep was reduced during the first 6 h of sleep, but not over the whole night. The number of substitutions in the digit symbol substitution test was decreased 9 h after ingestion of 7.5 and 10.0 mg, and the number of symbols copied reduced after 10.0 mg. The clinical dose range of zopiclone is likely to be up to 7.5 mg. The latter dose provides a useful hypnotic effect with minimal residual effects the next day, whilst 5.0 mg is appropriate for those involved in skilled tasks where even the most minor changes in performance during the early part of the next day must be avoided.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6669635     DOI: 10.1159/000137915

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  8 in total

1.  Noise-induced sleep maintenance insomnia: hypnotic and residual effects of zaleplon.

Authors:  Barbara M Stone; Claire Turner; Sue L Mills; Isabelle Paty; Alain Patat; Mona Darwish; Philippe Danjou
Journal:  Br J Clin Pharmacol       Date:  2002-02       Impact factor: 4.335

2.  Effect of zopiclone on sleep quality, morning stiffness, widespread tenderness and pain and general discomfort in primary fibromyalgia patients. A double-blind randomized trial.

Authors:  M Grönblad; J Nykänen; Y Konttinen; E Järvinen; T Helve
Journal:  Clin Rheumatol       Date:  1993-06       Impact factor: 2.980

3.  Hypnotic activity of an imidazo-pyridine (zolpidem).

Authors:  A N Nicholson; P A Pascoe
Journal:  Br J Clin Pharmacol       Date:  1986-02       Impact factor: 4.335

4.  Effects of zopiclone and temazepam on sleep, behaviour and mood during the day.

Authors:  E van der Kleijn
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 5.  Zopiclone. A review of its pharmacological properties and therapeutic efficacy as an hypnotic.

Authors:  A N Wadworth; D McTavish
Journal:  Drugs Aging       Date:  1993 Sep-Oct       Impact factor: 3.923

Review 6.  Zopiclone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy as an hypnotic.

Authors:  K L Goa; R C Heel
Journal:  Drugs       Date:  1986-07       Impact factor: 9.546

7.  Zopiclone in insomniac shiftworkers. Evaluation of its hypnotic properties and its effects on mood and work performance.

Authors:  T C Monchesky; B J Billings; R Phillips; J Bourgouin
Journal:  Int Arch Occup Environ Health       Date:  1989       Impact factor: 3.015

8.  Psychiatric medication and physical performance parameters - Are there implications for treatment?

Authors:  Anna Hirschbeck; Douglas Silva Leao; Elias Wagner; Alkomiet Hasan; Astrid Roeh
Journal:  Front Psychiatry       Date:  2022-09-06       Impact factor: 5.435

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.